These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9163940)

  • 41. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

  • 42. How does infliximab work in rheumatoid arthritis?
    Maini RN; Feldmann M
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S22-8. PubMed ID: 12110154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
    Gerlag DM; Tak PP
    Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
    Lorenz HM; Grünke M; Hieronymus T; Antoni C; Nüsslein H; Schaible TF; Manger B; Kalden JR
    J Rheumatol; 2000 Feb; 27(2):304-10. PubMed ID: 10685789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 46. [Tumor necrosis factor modulators in the treatment of rheumatoid arthritis].
    Konttinen YT; Valleala H; Honkanen V; Törnwall J; Tensing EK; Sorsa T; Nordström D
    Duodecim; 1999; 115(18):1969-76. PubMed ID: 11941814
    [No Abstract]   [Full Text] [Related]  

  • 47. [Molecular targeting therapy in rheumatoid arthritis].
    Mima T; Nakashima Y; Hanba Y; Ohya M; Negi S; Shigematsu T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):603-9. PubMed ID: 22991840
    [No Abstract]   [Full Text] [Related]  

  • 48. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

  • 49. The prospect for cytokine based therapeutic strategies in rheumatoid arthritis.
    Campion GV
    Ann Rheum Dis; 1994 Aug; 53(8):485-7. PubMed ID: 7944630
    [No Abstract]   [Full Text] [Related]  

  • 50. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts.
    Saevarsdottir S; Wedrén S; Seddighzadeh M; Bengtsson C; Wesley A; Lindblad S; Askling J; Alfredsson L; Klareskog L
    Arthritis Rheum; 2011 Jan; 63(1):26-36. PubMed ID: 20862678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The structural features and inhibitors of tumor necrosis factor-alpha converting enzyme].
    Du ZY; Li XY; Ye QZ
    Sheng Li Ke Xue Jin Zhan; 1999 Jul; 30(3):245-8. PubMed ID: 12532790
    [No Abstract]   [Full Text] [Related]  

  • 52. [TNF-alpha antagonist in rheumatoid arthritis. Joint destruction can be controlled].
    MMW Fortschr Med; 2003 Oct; 145(41):46. PubMed ID: 14655484
    [No Abstract]   [Full Text] [Related]  

  • 53. Rheumatoid arthritis.
    Burchini G; Orsi C
    N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
    [No Abstract]   [Full Text] [Related]  

  • 54. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Verhoeven AC; Boers M
    Ned Tijdschr Geneeskd; 2001 Nov; 145(47):2294-5. PubMed ID: 11760611
    [No Abstract]   [Full Text] [Related]  

  • 55. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis.
    Inoue K; Takano H; Yanagisawa R; Yoshikawa T
    Chest; 2003 Jul; 124(1):413-4; author reply 414. PubMed ID: 12853558
    [No Abstract]   [Full Text] [Related]  

  • 57. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections.
    Beenhouwer D; Wallis R; Broder M; Furst DE
    J Rheumatol; 2004 Oct; 31(10):1888-92. PubMed ID: 15487038
    [No Abstract]   [Full Text] [Related]  

  • 59. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Scand J Rheumatol; 2009; 38(1):66-7. PubMed ID: 18759163
    [No Abstract]   [Full Text] [Related]  

  • 60. Active tuberculosis in a patient with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitor.
    Fuchs I; Abu-Shakra M; Gelfer E; Smoliakov A; Ben-Haroch D; Horowitz J; Avnon LS
    Isr Med Assoc J; 2010 Sep; 12(9):579-81. PubMed ID: 21287806
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.